Actinium Pharmaceuticals, Inc.
Targeted Therapies for Patients with Unmet Needs
58 employees · est. 2000 · New York, United States
Actinium Pharmaceuticals, Inc. is the older company (2000 vs 2010); Actinium Pharmaceuticals, Inc. is the larger of the two.
Side-by-Side Comparison
| Metric | Actinium Pharmaceuticals, Inc. | Cantargia AB |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2010 |
| Headquarters | ||
| Headquarters | New York, United States | Lund, Sweden |
| Employees | ||
| Employees | 58 larger | 32 |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biotechnology, Health and Wellness, Medical Devices |
| Funding Stage | ||
| Funding Stage | Grant | Post Ipo Equity |
| Total Funding | ||
| Total Funding | Not tracked yet | $257.00M |
| Funding Rounds | ||
| Funding Rounds | 1 | 2 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Actinium Pharmaceuticals, NYSE: ATNM, Targeted Radioimmunotherapies, Advanced Cancers, AML, BMT Myeloablation, Hematopoeitic Stem Cell, Bone Marrow Transplant, Biopharmaceuticals, ADCs, Acute Myeloid Leukemia, Multiple Myeloma | Antibody-based Therapies, Clinical Programs, IL1RAP, Cancer Treatment, Autoimmune Diseases, Inflammatory Diseases, Leukemic Stem Cells, Hematopoietic Stem Cells, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Antibody-based Therapy, Swedish Listed Company, Phase II Development |
| Website | ||
| Website | actiniumpharma.com | cantargia.com |
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a biotechnology and pharmaceutical company based in the United States, founded in 2000. The company's mission is to develop innovative targeted radioimmunotherapies to address the unmet needs of patients with advanced cancers. Actinium Pharmaceuticals i...
About Cantargia AB
Cantargia is a Swedish listed biotechnology company that focuses on developing antibody-based therapies targeting IL1RAP. The company's clinical programs include nadunolimab, which is currently in phase II development for the treatment of cancer, and CAN10 in phase I development for autoimmune/infla...
We will tell you when either one moves
BounceWatch watches Actinium Pharmaceuticals, Inc. and Cantargia AB for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Actinium Pharmaceutica... and Cantargia AB — by email.
Frequently Asked Questions
Compare Actinium Pharmaceuticals, Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Actinium Pharmaceuticals, Inc. on 9 Jun 2026, and Cantargia AB on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
